First experience with the new extracorporeal membrane oxygenation system Colibrì

Abstract

AbstractIntroductionExtracorporeal membrane oxygenation (ECMO) is increasingly used for circulatory or pulmonary support not only in‐hospital but also out‐of‐hospital. Small dimensions and a lightweight design are important, especially for out‐of‐hospital use but also for intra‐hospital transportation of patients who require ECMO support. We share our first experience with the new Colibrì ECMO system.Patients and MethodsFrom December 2022 to January 2023, we used the new Colibrì extracorporeal circulation (ECC) system in six patients with cardiac or pulmonary failure.ResultsThe Colibrì system was used in‐hospital in six patients with post‐cardiac surgery low output syndrome, respiratory failure due to influenza or acute respiratory distress syndrome, cardiogenic shock, pulmonary embolism, and failed weaning from cardiopulmonary bypass. The system was implanted in venovenous (VV) and venoarterial (VA) fashion in 3 patients, respectively. In one patient, the configuration was switched from VA to VV after cardiac recovery. One patient received left‐ventricular unloading using the IMPELLA®5.5. ECMO run time was 1 to 13 days. We did not notice any ECC system‐associated complications. No ECMO system changes were required.ConclusionOur case series concludes that the new Colibrì system is safe and effective for in‐hospital ECMO indications. The small dimensions and lightweight design are very beneficial for the transportation of patients. It might be especially helpful for out‐of‐hospital situations.